Pfizer

Issued by Global Policy & Public Affairs, Pfizer Inc. -- Do Not Detail --
April 2023

Position on Expanded Access to Investigational Drugs

Background

Patients seeking preapproval access to investigational drugs often suffer from serious or immediately life-
threatening diseases or conditions. These patients may be willing to try an experimental drug for which robust
clinical information about efficacy is not yet available. These programs can be referred to by different names;
two...